|
515 Companies |
|
302 Products |
|
302 Products |
|
167 Mechanisms of Action |
|
1404 Trials |
|
125634 News |
|
| «12...15591560156115621563156415651566156715681569...15771578» |
- ||| Enrollment open: Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma (clinicaltrials.gov) - Jul 8, 2013
P=N/A, N=99, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Recruiting
- dovitinib (TKI258) / Novartis, Oncoheroes, sunitinib / Generic mfg.
Enrollment closed, Stroma, Metastases: Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258 (clinicaltrials.gov) - Jul 8, 2013
P2, N=30, Active, not recruiting, Sponsor: Asan Medical Center
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- cyclophosphamide / Generic mfg.
Enrollment closed: Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma (clinicaltrials.gov) - Jul 8, 2013
P1/2, N=44, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- || Biomarker, Enrollment change: Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor (clinicaltrials.gov) - Jul 7, 2013
P=N/A, N=185, Recruiting, Sponsor: Children's Oncology Group
Suspended --> Active, not recruiting N=100 --> 185
- ||| Biomarker, Enrollment open: Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor (clinicaltrials.gov) - Jul 7, 2013
P=N/A, N=185, Recruiting, Sponsor: Children's Oncology Group
N=100 --> 185 Not yet recruiting --> Recruiting
- mitomycin / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial termination, Metastases: Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus (clinicaltrials.gov) - Jul 7, 2013
P2, N=30, Terminated, Sponsor: Gynecologic Oncology Group
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated
- Avastin (bevacizumab) / Roche
New P2 trial: NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Jul 7, 2013
P2, N=40, Recruiting, Sponsor: Case Comprehensive Cancer Center
- ||||| Halaven (eribulin mesylate) / Eisai
Enrollment closed: Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma (clinicaltrials.gov) - Jul 1, 2013
P3, N=450, Active, not recruiting, Sponsor: Eisai Inc.
Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
- Enrollment closed, FDG PET, Stroma, Metastases: Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer (clinicaltrials.gov) - Jul 1, 2013
P1/2, N=380, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Zolinza (vorinostat) / Merck (MSD)
Enrollment closed: Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Jun 30, 2013
P1/2, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- | RG7112 / Roche
Trial completion, Combination therapy: A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 30, 2013
P1, N=23, Completed, Sponsor: Hoffmann-La Roche
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- erlotinib / Generic mfg.
Trial completion: Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma (clinicaltrials.gov) - Jun 30, 2013
P1/2, N=36, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- 7-Hydroxystaurosporine (UCN-01) / National Cancer Institute
Trial completion, Combination therapy, Metastases: 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (clinicaltrials.gov) - Jun 30, 2013
P1, N=41, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas (clinicaltrials.gov) - Jun 30, 2013
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- cytarabine / Generic mfg.
Enrollment change: Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma (clinicaltrials.gov) - Jun 27, 2013
P2, N=10, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=20 --> 10
- Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy, Metastases: Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer (clinicaltrials.gov) - Jun 27, 2013
P1/2, N=73, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=20 --> 10 Completed --> Active, not recruiting
- ENMD-2076 / CASI
Enrollment open, Metastases: Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 26, 2013
P2, N=25, Recruiting, Sponsor: University Health Network, Toronto
Completed --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| Enrollment change, Metastases: High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma (clinicaltrials.gov) - Jun 26, 2013
P3, N=109, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting N=75 --> 109
- Enrollment change, Metastases: Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma (clinicaltrials.gov) - Jun 26, 2013
P3, N=0, Withdrawn, Sponsor: Children's Oncology Group
N=75 --> 109 N=528 --> 0
- doxorubicin hydrochloride / Generic mfg.
Trial completion: Pharmacokinetic Study of Doxorubicin in Children With Cancer (clinicaltrials.gov) - Jun 26, 2013
P2, N=101, Completed, Sponsor: University Hospital Muenster
N=528 --> 0 Active, not recruiting --> Completed
- |||| brivanib alaninate (BMS-582664) / ZAI Lab
Trial completion, Metastases: Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types (clinicaltrials.gov) - Jun 25, 2013
P2, N=597, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Active, not recruiting --> Completed
- RG7112 / Roche
Enrollment change, Combination therapy: A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 24, 2013
P1, N=23, Completed, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed N=36 --> 23
- New P2 trial: Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma (clinicaltrials.gov) - Jun 23, 2013
P2, N=20, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- || Mepact (mifamurtide) / Takeda
Enrollment change: Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=205, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
N=36 --> 23 N=100 --> 205
- ||| Mepact (mifamurtide) / Takeda
Trial completion: Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma (clinicaltrials.gov) - Jun 20, 2013
P=N/A, N=205, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
N=100 --> 205 Active, not recruiting --> Completed
- Enrollment open: Proton Radiation Therapy for Spinal Tumors (clinicaltrials.gov) - Jun 20, 2013
P2, N=34, Recruiting, Sponsor: University of Florida
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Autologous dendritic cell vaccine / N.N. Petrov National Medical Research Center of Oncology
New P2 trial: ADCVCTAST: Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Jun 19, 2013
P2, N=48, Recruiting, Sponsor: Petrov Research Institute of Oncology
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Avastin (bevacizumab) / Roche, Neulasta (pegfilgrastim) / Roche
Enrollment open, Surgery: RMS13: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (clinicaltrials.gov) - Jun 19, 2013
P2, N=48, Recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| Enrollment closed: ARST0531: Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma (clinicaltrials.gov) - Jun 18, 2013
P3, N=486, Active, not recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial withdrawal: Markers of Anthracycline-Related Cardiac Muscle Injury (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- Enrollment change: Markers of Anthracycline-Related Cardiac Muscle Injury (clinicaltrials.gov) - Jun 17, 2013
P=N/A, N=0, Withdrawn, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Withdrawn N=36 --> 0
- ||||| Enrollment change: Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma (clinicaltrials.gov) - Jun 17, 2013
P3, N=390, Active, not recruiting, Sponsor: Children's Oncology Group
N=36 --> 0 N=510 --> 390
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed: Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor (clinicaltrials.gov) - Jun 17, 2013
P3, N=416, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
N=510 --> 390 Recruiting --> Active, not recruiting
- ||||| Zolinza (vorinostat) / Merck (MSD)
New P1/2 trial, P1/2 data, Combination therapy, Metastases: GemTax: Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma (clinicaltrials.gov) - Jun 13, 2013
P1/2, N=67, Recruiting, Sponsor: Hussein Tawbi
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: A Phase II Study of Anlotinib in STS Patients (clinicaltrials.gov) - Jun 13, 2013
P2, N=200, Recruiting, Sponsor: Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- ||||| Enrollment change: Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma (clinicaltrials.gov) - Jun 12, 2013
P3, N=702, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting N=518 --> 702
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion: QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors (clinicaltrials.gov) - Jun 12, 2013
P2, N=38, Completed, Sponsor: Amgen
N=518 --> 702 Active, not recruiting --> Completed
- ||||| ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Enrollment change, Surgery: EURAMOS-1: Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma (clinicaltrials.gov) - Jun 11, 2013
P3, N=1164, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=2300 --> 1164
- ||| Biomarker, Enrollment open: Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=1650, Recruiting, Sponsor: Children's Oncology Group
N=2300 --> 1164 Not yet recruiting --> Recruiting
- Trial withdrawal: Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Not yet recruiting --> Recruiting Recruiting --> Withdrawn
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial termination: MT2004-30: Tomotherapy for Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=23, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Withdrawn Active, not recruiting --> Terminated; Replaced by another study
- | Torisel (temsirolimus) / Pfizer
Trial initiation date, Stroma: COMTT: Caphosol in Oral Mucositis Due to Targeted Therapy (clinicaltrials.gov) - Jun 10, 2013
P3, N=60, Recruiting, Sponsor: Christine B Boers-Doets
Active, not recruiting --> Terminated; Replaced by another study Initiation date: Feb 2011 --> Sep 2011
- || Trial initiation date: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=906, Recruiting, Sponsor: Children's Oncology Group
Initiation date: Feb 2011 --> Sep 2011 Initiation date: May 2007 --> May 2008
- Enrollment change: Acupuncture Point Stimulation for Treatment of Chemotherapy Nausea and Vomiting (clinicaltrials.gov) - Jun 10, 2013
P=N/A, N=0, Withdrawn, Sponsor: Stanford University
Initiation date: May 2007 --> May 2008 N=35 --> 0
- Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, Votrient (pazopanib) / Novartis, BeiGene
Enrollment change: Study of Pazopanib and Ixabepilone in Patients With Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=31, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
N=35 --> 0 N=75 --> 31
- Leukine (sargramostim) / Partner Therap, Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment change: MT2004-30: Tomotherapy for Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=23, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
N=75 --> 31 N=45 --> 23
- Aplidin (plitidepsin) / PharmaMar, Roche
New P2 trial, Metastases: Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial (clinicaltrials.gov) - Jun 10, 2013
P2, N=24, Terminated, Sponsor: Institut Bergoni
- rhIL-15 / National Cancer Institute
New P1 trial, Metastases: NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=51, Recruiting, Sponsor: National Cancer Institute (NCI)
- rhIL-15 / National Cancer Institute
Enrollment open, Metastases: NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors (clinicaltrials.gov) - Jun 10, 2013
P1, N=51, Recruiting, Sponsor: National Cancer Institute (NCI)
N=45 --> 23 Not yet recruiting --> Recruiting
- ||| Kisqali (ribociclib) / Novartis
Enrollment open: Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma (clinicaltrials.gov) - Jun 10, 2013
P1, N=64, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting